170 related articles for article (PubMed ID: 33129590)
1. Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules.
He ZX; Gong YP; Zhang X; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112946. PubMed ID: 33129590
[TBL] [Abstract][Full Text] [Related]
2. Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors.
Kim EY; Kang ST; Jung H; Park CH; Yun CS; Hwang JY; Byun BJ; Lee CO; Kim HR; Ha JD; Ryu DH; Cho SY
Arch Pharm Res; 2016 Apr; 39(4):453-464. PubMed ID: 26753914
[TBL] [Abstract][Full Text] [Related]
3. Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review.
Garrido A; Vera G; Delaye PO; Enguehard-Gueiffier C
Eur J Med Chem; 2021 Dec; 226():113867. PubMed ID: 34607244
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
[TBL] [Abstract][Full Text] [Related]
5. Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.
Ahmed EM; Khalil NA; Taher AT; Refaey RH; Nissan YM
Bioorg Chem; 2019 Nov; 92():103272. PubMed ID: 31539742
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, molecular modelling and anticancer evaluation of new pyrrolo[1,2-b]pyridazine and pyrrolo[2,1-a]phthalazine derivatives.
Popovici L; Amarandi RM; Mangalagiu II; Mangalagiu V; Danac R
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):230-243. PubMed ID: 30734610
[TBL] [Abstract][Full Text] [Related]
7. Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities.
Jaballah MY; Serya RAT; Saad N; Khojah SM; Ahmed M; Barakat K; Abouzid KAM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1573-1589. PubMed ID: 31852269
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors.
Mao B; Gao S; Weng Y; Zhang L; Zhang L
Eur J Med Chem; 2017 Mar; 129():135-150. PubMed ID: 28235701
[TBL] [Abstract][Full Text] [Related]
9. Design and Synthesis of Pyridazine Containing Compounds with Promising Anticancer Activity.
Elmeligie S; Ahmed EM; Abuel-Maaty SM; Zaitone SA; Mikhail DS
Chem Pharm Bull (Tokyo); 2017; 65(3):236-247. PubMed ID: 28250345
[TBL] [Abstract][Full Text] [Related]
10. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
[TBL] [Abstract][Full Text] [Related]
11. Pyridazine based inhibitors of p38 MAPK.
McIntyre CJ; Ponticello GS; Liverton NJ; O'Keefe SJ; O'Neill EA; Pang M; Schwartz CD; Claremon DA
Bioorg Med Chem Lett; 2002 Feb; 12(4):689-92. PubMed ID: 11844702
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents.
Zhou S; Liao H; He C; Dou Y; Jiang M; Ren L; Zhao Y; Gong P
Eur J Med Chem; 2014 Aug; 83():581-93. PubMed ID: 24996144
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
14. Thiazolo[4,5-d]pyridazine analogues as a new class of dihydrofolate reductase (DHFR) inhibitors: Synthesis, biological evaluation and molecular modeling study.
Ewida MA; Abou El Ella DA; Lasheen DS; Ewida HA; El-Gazzar YI; El-Subbagh HI
Bioorg Chem; 2017 Oct; 74():228-237. PubMed ID: 28865294
[TBL] [Abstract][Full Text] [Related]
15. New derivatives of pyrrolo[3,4-d]pyridazinone and their anticancer effects.
Malinka W; Redzicka A; Lozach O
Farmaco; 2004 Jun; 59(6):457-62. PubMed ID: 15178308
[TBL] [Abstract][Full Text] [Related]
16. Novel 3-arylamino- and 3-cycloalkylamino-5, 6-diphenyl-pyridazines active as ACAT inhibitors.
Toma L; Giovannoni MP; Vergelli C; Dal Piaz V; Kwon BM; Kim YK; Gelain A; Barlocco D
Arch Pharm (Weinheim); 2002; 335(11-12):563-6. PubMed ID: 12596221
[TBL] [Abstract][Full Text] [Related]
17. Diverse Pharmacological Potential of Pyridazine Analogs against Various Diseases.
Alsaiari AA; Almehmadi MM; Asif M
Med Chem; 2024; 20(3):245-267. PubMed ID: 37711126
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
Martínez-González S; Rodríguez-Arístegui S; Gómez de la Oliva CA; Hernández AI; González Cantalapiedra E; Varela C; García AB; Rabal O; Oyarzabal J; Bischoff JR; Klett J; Albarrán MI; Cebriá A; Ajenjo N; García-Serelde B; Gómez-Casero E; Cuadrado-Urbano M; Cebrián D; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2019 Apr; 168():87-109. PubMed ID: 30802730
[TBL] [Abstract][Full Text] [Related]
19. Pyridazine Based Scaffolds as Privileged Structures in anti-Cancer Therapy.
Jaballah MY; Serya RT; Abouzid K
Drug Res (Stuttg); 2017 Mar; 67(3):138-148. PubMed ID: 28073115
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds.
Okaniwa M; Hirose M; Imada T; Ohashi T; Hayashi Y; Miyazaki T; Arita T; Yabuki M; Kakoi K; Kato J; Takagi T; Kawamoto T; Yao S; Sumita A; Tsutsumi S; Tottori T; Oki H; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
J Med Chem; 2012 Apr; 55(7):3452-78. PubMed ID: 22376051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
